In yesterday’s Wall Street session, Anavex Life Sciences Corporation (NASDAQ:AVXL) shares traded at $10.87, down -2.77% from the previous session.
AVXL stock price is now 38.62% away from the 50-day moving average and 91.55% away from the 200-day moving average. The market capitalization of the company currently stands at $896.38M.
With the price target reduced from $16 to $11, Cantor Fitzgerald Downgraded its rating from Overweight to Neutral for Anavex Life Sciences Corporation (NASDAQ: AVXL). On June 23, 2022, Berenberg recently initiated its ‘Buy’ rating on the stock quoting a target price of $40, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Donhauser Peter D.O., Director bought 2,835 shares of the company’s stock on Jun 14 ’24. The stock was bought for $10,319 at an average price of $3.64. Upon completion of the transaction, the Director now directly owns 5,000 shares in the company, valued at $54350.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, Director Thomas Steffen bought 5,000 shares of the business’s stock. A total of $22,600 was incurred on buying the stock at an average price of $4.52. This leaves the insider owning 5,000 shares of the company worth $54350.0. A total of 3.18% of the company’s stock is owned by insiders.
During the past 12 months, Anavex Life Sciences Corporation has had a low of $3.25 and a high of $11.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.86, and a quick ratio of 8.86. The fifty day moving average price for AVXL is $7.7284 and a two-hundred day moving average price translates $5.645425 for the stock.
The latest earnings results from Anavex Life Sciences Corporation (NASDAQ: AVXL) was released for 2024-06-30. The company reported revenue of $14.73 million for the quarter, compared to $13.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.85 percent.
